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Abstract 
Tacrine (THA) and physostigmine (PHS) have been used in Alzheimer's disease therapy for their anticholinesterasic activity. Here we 
show that THA is taken up in rat lysosomes in an energy-dependent manner, and that it is also accumulated in acidic compartments of rat 
thymocytes and neuroblastoma cells. A concentration of THA less than 1 mM dissipated the pH gradient (ApH) in all the above 
mentioned in vitro systems. On the contrary higher concentrations of PHS (1-2 mM) were ineffective. The accumulation of THA in 
acidic organelles of the cell may be relevant for the pharmacological action of THA in Alzheimer's treatment. 
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1. Introduction 
Alzheimer's disease (AD) is associated with severe 
impairment on the activity of different physiological and 
biochemical processes in the brain. Among different phar- 
macological strategies used in AD treatment suggested by 
the biochemical changes found in the cholinergic system, 
the most promising results were obtained using anti- 
cholinesterasic compounds, such as physostigmine (PHS) 
and tacrine (THA) [1]. 
THA has been shown to possess the most promising 
therapeutic efficacy, in spite of its lower in vivo [2] and in 
vitro [3] inhibitory effect of cholinesterase activity com- 
pared to PHS. This observation suggested that the 
cholinesterase inhibition in the synaptic left may not be 
the only effect of THA. A multiple action mechanism has 
been recently suggested for THA, including effects on the 
cholinergic system, interaction with cholinergic receptors, 
effects on the monoaminergic system, inhibition on the 
release and uptake of catecholamines and serotonin [3]. 
In the present study we focused our interest on the 
localization of THA and PHS in the cell. It is well known 
that the a typical eukariotic cell contains many acidic 
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organelles belonging both to the endocytic and the secre- 
tory pathway [4]. THA is a weak base (pK a = 10); pro- 
vided that its unprotonated neutral form is membrane 
permeant, he drug is expected to accumulate inside acid 
organelles by protonation, as acridine orange (AO) [5-7] 
and other amines do, following the classic mechanism 
proposed for the uptake of weak bases in the lysosomes 
[8,9]. 
In order to investigate such a hypothesis, we tested the 
effect of THA and PHS on the accumulation of the dye 
acridine orange in rat liver lysosomes and acidic compart- 
ments of rat thymocytes or neuroblastoma cells. 
In addition, the drug accumulation i some of the above 
systems was also measured. We found that THA, but not 
PHS accumulated both in lysosomes and in acidic com- 
partments of the cell. The relevance of this finding with 
respect o a possible action mechanism of THA will be 
discussed. 
2. Materials and methods 
Tacrine (9-amino,l,2,3,4-tetrahydroacridine) a d 
physostigmine (Scheme 1) were purchased by Aldrich. 
Nigericin was obtained from Sigma. 
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Scheme 1. 
Rat liver lysosomes were prepared by centrifugation i
a self generating Percoll (Sigma) gradient [6], from a 
lysosome nriched preparation, and resuspended in Hepes 
buffer 20 mM pH 7.4 containing KC1 (or, as specified, 
choline-Cl 125 mM), and MgC12 4 mM. 
Rat thymocytes were isolated as previously described 
[10] from male Wistar rats weighing 150-200 g. Cells 
were mantained at room temperature in a simplified saline 
solution containing NaC1 135 mM, KCI 5 mM, NaHCO 3 5 
mM, glucose 5.5 mM, MgC12 4 mM, Hepes buffer 20 mM 
pH 7.4 or, in some cases, in the some medium without 
glucose and containing oligomycin 1.5/zg/ml. Cell viabil- 
ity was > 95%, also after two or more hours of incubation 
in either medium. Protein assay was carried out using the 
classic biuret method [11] and bovine serum albumin as a 
standard. 
Murine neuroblastoma C 1300 (clone Neuro 2A) cells 
(N2A) were obtained from the American Type Culture 
Collection. Cells were grown in Dulbecco's modified 
medium (DMEM) and resuspended, before use, in the 
glucose medium described above. 
Acridine Orange (AO) (Aldrich) uptake by lysosomes 
(ATP-driven) and by rat thymocytes was monitored spec- 
trophotometrically as previously described [5,7]. To deter- 
mine the amount of AO taken up by lysosomes, a suspen- 
sion of these organelles was centrifuged at 30 000 × g for 
15 min (Sorvall RC 2B, 5534), 20 min after from the 
addition of 2 mM ATP. AO in the supernatant was esti- 
mated by measuring the absorbance at 492 nm using a 
calibration curve. Since THA and PHS do not absorb in 
the visible spectral region nor affect he AO absorbance (at 
492 nm), this allowed the use of AO, as zapH probe, in the 
presence of the drugs. To measure THA or PHS uptake by 
thymocytes, cells treated with the drug for 30 min, were 
centrifuged at low speed; the supematant was then supple- 
mented with 3% HC104 to eliminate residual protein con- 
tent and centrifuged as described for lysosomes. THA or 
PHS concentrations in the supernatant were measured at 
335 and 320 nm respectively, using a calibration curve. A 
similar procedure was followed to measure THA uptake by 
lysosomes except hat lysosomes were removed by centrif- 
ugation at 30 000 × g, following a 20 min incubation with 
the drug. Cells or lysosomes incubation with the drugs 
were performed at 37 ° C, AO uptake at room temperature. 
Unless otherwise indicated, experiments were carried out 
at least three times using each time a new preparation of 
lysosomes or cells. 
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Fig. 1. ATP driven uptake of AO by rat liver lysosomes; effect on the uptake of THA, PHS and NH + (a,b,c). (d) Percent of the reversal of the dye uptake 
by THA as a function of  drug concentration. Lysosomes were resuspended in a medium as described in Materials and methods at a protein concentration f
0,4 mg/ml .  The dye uptake was monitored as Aabsorbance using 492 nm as a measuring wawelength and 550 nm as reference. Additions: AO 5 ~M, 
ATP 1 mM, THA as indicated in the figure, NH~ 20 raM, PHS 1 mM. 
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3. Results 
3.1. Dissipation of ApH by THA 
Fig. 1 reports the acidification of rat liver lysosomes 
produced by the H+-ATPase pump as monitored photo- 
metrically by using the ApH probe AO. Addition of NH~ 
which is know to dissipate the ApH (trace a) or of THA 
(trace b) elicited the release of the AO dye, reflecting a 
collapse of the ApH. A similar effect was observed with 
nigericin 1 /xg/ml (not shown, see [5]). PHS on the 
contrary, did not show such an effect (trace c). 50% and 
100% dye release was caused by about 0.15 mM and 
0.8-1 mM THA, respectively (Fig. ld). 
Fig. 2 shows the acidification of lysosomes (using a 
K+-free medium) mediated by nigericin, which causes a 
H ÷ uptake in exchange with intralysosomal K ÷. Addition 
of THA, similarly to NH~, reversed the change in dye 
absorbance, indicating that the effect of THA on dpH 
shown in Fig. 1 was not due to the inhibition of lysosomal 
H+-ATPase, but rather to the accumulation of THA as a 
weak base into lysosomes. 
The uptake of AO in the lysosomes, caused by the 
H+-ATPase and the consequent release of the dye by 
THA, were measured in the supernatant upon centrifuga- 
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Fig. 2. Effect of THA or NH2 on nigericin elicited pH gradient in rat 
liver lysosomes. Lysosomes ata protein concentration f 0.5 mg/ml, 
were resuspended in a K+-free medium prepared in Hepes buffer 20 mM 
pH 7.4 and containing choline-chloride 125 raM, MgC12 5 raM. The 
ApH was created by addition of nigericin (1 /xg/ml). AO and NH2 
additions as in Fig. 1, THA addition as indicated. 
Table 1 
ATP-driven uptake of AO by lysosomes and the dye release by NH~ or 
THA 
Conditions AO uptake (nmol/mg protein) 
Control 17.4 + 1.5 
ATE' 2 mM 36.7+3.2 
ATP 2 mM+NH~ 15.4-t- 1.5 
ATP 2 mM + THA 16.2+ 1.8 
Lysosomes, incubated for 20 min with 10 /.LM AO in the absence or 
presence ofATP were then treated with 700 ~M THA or 20 mM NH2 
or did not receive any addition. Few min later (4-5), the lysosomes 
suspension was centrifuged asdescribed in Materials and methods. Inthe 
absence of ATP, NH~ or THA had no effect on the dye uptake (not 
shown). Data + S.D. refer to at least hree xperiments using each time a 
different preparation. 
tion of the lysosomal suspension. ATP strongly increased 
the dye uptake by lysosomes and the following addition of 
THA or NH ~, reversed the above-mentioned increase (Ta- 
ble 1). 
Fig. 3 shows a spectrophotometric analysis of the up- 
take of AO by rat thymocytes and of its accumulation i to 
acidic compartments. This phenomenon is probably a re- 
sult of both passive and active transport. Even in this 
system THA or NH~ traces a, b) or nigericin (not shown, 
see [7]) reversed the dye uptake, while PHS was totally 
ineffective. 50% and 100% dye release was caused by 
about 0.3 mM and 0.8-1 mM THA respectively (Fig. 3c). 
In cells incubated for 2 h in a glucose-free medium 
supplemented with the mitochondrial ATP-synthetase in- 
hibitor oligomycin the dye uptake was strongly (70-80%) 
inhibited (trace d). This finding further strengthens the 
view that the dye accumulation i volves intracellular acidic 
compartments. AO uptake was also (spectrophotometri- 
cally) assessed in N2A cells; a consistent dye uptake by 
these cells was found, that was completely reversed by 
THA, at the concentrations described above, indicating 
that the drug was able to dissipate intracellular pH gradi- 
ents also in these cells (Fig. 3, trace e). 
3.2. THA uptake by lysosomes or thymocytes 
Further evidence of THA accumulation i side the lyso- 
somes or in the acidic compartments of thymocytes was 
obtained by a direct measurement of THA uptake (Table 
2). Differently from AO, THA was taken up by lysosomes 
at a low level in the absence of ATP, but a consistent 
increase in THA uptake was observed when ATP was 
present. As expected, NH~ or nigericin released the drug 
accumulated in the lysosomes through the ATP-driven 
proton pump. A comparative study of THA or PHS uptake 
by thymocytes i also presented in Table 2. The uptake of 
the THA was partially reversed by NH~ Conversely 
nigericin greatly increased the extent of THA uptake, 
despite the fact that, under the same conditions, the 
ionophore does collapse the ApH, as above mentioned. 
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Table 2 
Uptake of THA and PHS by lysosomes and/or thymocytes 
Preparations Conditions Uptake (nmol/mg protein 
(a) or nmol/10 6
cells (b)) of 
THA PHS 
(a) Lysosomes 
(b) Thymocytes 
control 0.21 + 0.04 (8) 
+ATP 2 mM 20.2+2.5 
+ ATP + NH~ 0.25 + 0.03 
+ ATP + nigericin 0.25 + 0.03 
control 0.42 + 0.07 (8) 
NH~ 0.11 +0.04 (8) 
nigericin 0.82 ± 0.1 
nigericin + NH~ 0.25 ± 0.05 
- glucose + oligomycin 0.19 + 0.07 (4) 
< 0.05 
< 0.05 
Effects of NH~, nigericin or metabolic inhibitors. NH~ (20 mM) or 
nigericin (1.5 /~g/ml) were added (when indicated) after incubation of 
lysosomes (20 rain) or thymocytes (30 min) with THA or PHS 80 /xM 
(as indicated). 4-5 min later, the suspension was centrifuged and further 
processed as described in Materials and methods. The last line shows 
THA uptake by cells incubated at room temperature for 2 h in a 
glucose-free medium supplemented with oligomycin 1.5 ~g/ml. No 
change in average THA uptake by thymocytes (in the standard medium) 
was detected even 2 h after cell preparation. Therefore, data obtained at 2 
h were included in the average (line 1). Unless otherwise indicated 
(number between brackets), data + S.D. refer to at least hree experiments 
using different lysosomes or cell preparations. 
This effect of nigericin can be easily explained by consid- 
ering that nigericin, at low external potassium concentra- 
tion, causes a cytoplasmic acidification [12] which in turn 
drives THA uptake into the cytoplasmic ompartment. 
Addition of NH + caused a partial reversion of the THA 
uptake induced by nigericin. 
In Table 2 is also shown that when cells were incubated 
for 2 h in a glucose-free medium containing the mitochon- 
drial ATP-synthetase inhibitor oligomycin, a consistent 
lowering (on an average, about 60% of the total, 75% of 
the NH~--sensitive fraction) of THA uptake by cells (in 
respect o cells incubated in the standard medium) was 
observed, similar in extent o that of AO (see Fig. 3d). 
PHS uptake by thymocytes was much lower than that of 
THA and unaffected by NH~. 
4. Discussion 
Our findings indicate that the anticholinesterasic drug 
THA enters isolated rat liver lysosomes and rat thymocytes 
or N2A cells whereby it accumulates inside acidic vesicles.. 
In intact cells this was indirectly supported by the finding 
that in metabolically inhibited cells we found a strong 
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Fig. 3. AO uptake by rat thymocytes or N2A cells; uptake reversal by THA and NH~. The dye (10 p~M) was added to a cuvette containing (a,b,d) 
thymocytes (33.106 cells/ml), (e) N2A cells (3.4. ]06/ml), suspended in the medium as described in Materials and methods. The decrease in absorbance 
(492-550 nm) (following the sudden absorbance hange due to the dye addition), reported in the figure, reflects the dye uptake by cells. (c) Reversal of 
dye uptake by TI-IA, in experiments u ing thymocytes, i  plotted as a function of the drug concentrations. (d)AO uptake by thymocytes incubated for 2 h 
about in a glucose-free medium supplemented with 1.5 p~g/ml oligomycin. Cells maintained atroom temperature for 2 h in the standard medium did not 
show any shown change in dye uptake (not shown) with respect to the initial value NH~ additions as in Fig. 1, THA and PHS additions as indicated. 
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inhibition of THA uptake similar in extent to that seen 
with AO (that, as it is well known, accumulates in acidic 
vesicles [7]. The finding that a similar result was observed 
using different cell types strongly supports that the mecha- 
nism involved in drug accumulation is unspecific and 
likely that proposed for weak bases uptake by the cell 
lysosomes [9]. Conversely, a different anticholinesterasic 
drug, PHS, is unable to accumulate in acidic compartments 
under the same conditions. This was largely unexpected 
considering the pK a values of the two dissociable protons 
of this drug (pK 1 7.9, pK 2 = 1.89 [13]). However, consid- 
ering the high lipophilicity of this drug (data not shown), 
the failure of the drug to accumulate could be due to a 
high membrane permeability of the charged form too, that 
should prevent rapping by protonation. The different be- 
haviour of the two drugs rises the question whether our 
results can be relevant with respect o the different hera- 
peutic efficacy reported for the two drugs [3]. Any modifi- 
cation on the lumenal pH of acidic compartments of the 
cell induced by the drug itself should play a minor role, 
considering that the drug concentration required to signifi- 
cantly affect pH is much higher than that used in clinical 
trials (< 1 /~M) [3]. However, the observation that acidic 
compartments are the primary targets of THA, but not 
PHS, may carry other relevant implications for the action 
mechanism of the drugs. 
It is well known that most vesicles belonging to the 
secretory pathway, including cholinergic synaptic vesicles 
of neuronal cells, have a low lumenal pH [14-18]. This is 
also most likely true for the 'large dense core' neuronal 
secretory vesicles, which differ from the above and are 
considered very similar to the secretory vesicles of the 
endocrine cells [19]. These organelles contain a variety of 
substances including neurotransmitter processing enzymes 
[20,21]. Moreover, acetylcholinesterase is secreted from 
neuronal structures such as subcisternal dendritic vesicles 
[22,23]. Thus, it can be speculated that THA is released 
into the synaptic cleft together or concomitantly with 
neurotransmitters and this might provide a high drug con- 
centration i  the synaptic left where the action of the drug 
is required. Another possibility is that the drug could 
interact in a more favorable condition, due to its higher 
concentration, with acetylcholinesterase or other enzymes 
involved in the cholinergic transmission, inside secretory 
vesicles. In addition one could speculate that the accumula- 
tion inside intracellular vesicles results in a longer avail- 
ability of the drug, prolonging therefore its pharmacologi- 
cal effects, by release of drug while its concentration 
becomes progressively lower in the extracellular space. 
This observation is consistent with the different half-life 
reported for THA (3-4 h) and for PHS (30 min) [24]. 
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